Gene set enrichment analysis of genome wide association data identifies novel biological pathways associated with Barrett's Oesophagus, and subsequent progression to dysplasia and adenocarcinoma
Findlay J. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 50 - 50
Genomic biomarkers of Barrett's Oesophagus metaplasia, dysplasia and malignant progression: a meta-analysis
Findlay J. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 39 - 39
Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure-adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor
Zhou X. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 105 - 106
First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma
Middleton M. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 117 - 117
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.
Dooley AJ. et al, (2014), Ther Adv Med Oncol, 6, 262 - 266
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
Gao S. et al, (2014), Cancer Res, 74, 5866 - 5877
A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
Middleton M. et al, (2014), CANCER RESEARCH, 74
Baseline 18F-FDG PET-CT factors associated with progression to metastatic disease during neoadjuvant therapy for esophageal cancer
Findlay JM. et al, (2014), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S233 - S233
OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS
Leijen S. et al, (2014), BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78, 769 - 769
The added value of 18F-FDG PET-CT in restaging esophageal cancer after neoadjuvant therapy
Findlay JM. et al, (2014), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S524 - S524
Translational Modelling of Vemurafenib, Selumetinib and Docetaxel in Metastatic Melanoma with Virtual Tumour Clinical
Brightman F. et al, (2014), JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 41, S64 - S64
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L. et al, (2014), Clin Cancer Res, 20, 4251 - 4261
Individual risk modelling for esophagectomy: a systematic review.
Findlay JM. et al, (2014), J Gastrointest Surg, 18, 1532 - 1542
Ipilimumab associated colitis: a modern mimic of Inflammatory Bowel Disease (IBD)
Tripathi M. et al, (2014), VIRCHOWS ARCHIV, 465, S235 - S236
A decision tree analysis of selective endoscopic ultrasound in staging oesophageal cancer
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 18 - 19
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG. et al, (2014), Lancet Oncol, 15, 620 - 630
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A. et al, (2014), Ann Oncol, 25, 968 - 974
The utility of restaging PET-CT In predicting progression to unresectable oesophageal cancer after neoadjuvant chemotherapy
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 19 - 19
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R. et al, (2014), Br J Dermatol, 170, 997 - 999